← Back to all trials
Recruiting
NCT07226154
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
Conditions: Pancreatic Ductal Adenocarcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 200
Sponsor: City of Hope Medical Center
Location: City of Hope Medical Center Duarte California
Summary
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
* Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
* Availability of pre-treatment plasma samples.
* Underwent curative-intent resection (R0 or R1).
Exclusion Criteria:
* Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
* Non-adenocarcinoma histology.
* Presence of synchronous or multiple primary malignancies.
* Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
* Presence of active inflammatory or autoimmune diseases.
Source: ClinicalTrials.gov (NCT07226154). StuddyBuddy aggregates publicly available trial information.
